Patent ID: 8658384

Claim:
A method of determining risk of experiencing a major adverse cardiac event (MACE), in a patient, within one year from presentation of at least one symptom of acute coronary syndrome (ACS) comprising the steps of: a) obtaining a test sample from said patient; b) determining the amount of at least three biomarkers selected from the group consisting of cardiac Troponin I (cTnI), pro-B-type natriuretic peptide (proBNP) or a cleavage product thereof, high sensitivity C reactive protein (hsCRP), myeloperoxidase (MPO), placental growth factor (PlGF), estimated glomerular filtration rate (eGFR), homocysteine (HCY), choline, ischemia modified albumin (IMA), soluble CD40 ligand (sCD40L) and lipoprotein-associated phospholipase A 2 (LpPLA2) in said test sample; and c) comparing the amount of said at least three biomarkers to biomarker reference standards, wherein said risk is determined by results of said comparison.